Hanmi Pharmaceutical Co., Ltd.

Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Pro > Luxeptinib G3 Formulation Achieves Desired Levels and Positions for Future Trials ConferenceCallandWebcastat5:00pmETToday SAN DIEGO and TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and year ended December 31, 2023, and provided a corporate update. “The data we have generated from tuspetinib thus far – as a single agent and in combination therapy with venetoclax in relapsed and refractory AML – have demonstrated a distinctly favorable safety pro broad activity for tuspetinib across mutational subtypes. This pro extends to FLT3 wildtype AML, which represents the majority of AML patients, and in which few agents have shown such broad activity,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. “These data have propelled us to initiate a clinical study of tuspetinib in a triplet combination with venetoclax and azacitidine in frontline therapy for newly diagnosed AML, including both FLT3 wild type and FLT3 mutated subtypes.” KeyCorporateHighlights Aptose Completes Public Offering – On January 30, 2024, Aptose closed a public offering of 5,649,122 common shares of the Company and warrants at a combined offering price of US $1.71 per share. This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option. Total gross proceeds from the public offering were approximately $9.7 million before deducting underwriting costs, placement agent commissions and other offering-related expenses. Private Placement– On January 31, 2024, Aptose closed a US $4 million private placement of common shares with strategic partner Hanmi Pharmaceutical. Under the terms of the strategic investment, Hanmi purchased each common share at a price of US $1.90, representing an 11% premium over the price of the common shares issued as part of the public offering. The Company also issued Hanmi warrants to purchase common shares at an exercise price of US $1.71 per warrant share. Total gross proceeds from the private placement were approximately $4 million, excluding underwriting discounts, placement agent commissions and other offering-related expenses. Tuspetinib Advancing to Triplet Therapy Pilot Study – Tuspetinib (TUS), a once daily oral agent with a unique kinase targeting pattern, is being developed for the treatment of patients with acute myeloid leukemia (AML). More than 170 patients to date received TUS alone or in combination with the BCL-2 inhibitor venetoclax (VEN) during the Phase 1/2 clinical program in the very ill relapsed or refractory (R/R) AML patient population. At the single agent 80 mg recommended Phase 2 dose, TUS achieved a favorable safety pro a CR/CRh rate of 36% among patients who were naive to VEN. The safety pro TUS remained favorable when TUS was combined with VEN in R/R AML patients, and responses were achieved in both patients naive to VEN and those who failed prior therapy with VEN. TUS avoids many typical toxicities observed with other agents and achieves broad activity across AML patients with a diversity of adverse genetics. Tuspetinib is now being advanced to a triplet combination therapy of tuspetinib, venetoclax and a hypomethylating agent (TUS/VEN/HMA) for the frontline treatment of newly diagnosed AML patients ineligible for induction chemotherapy. Luxeptinib G3 Evaluation Completed – During 2023 and early 2024, clinical evaluation of the new generation 3 (G3) formulation of luxeptinib (LUX) was completed. The G3 formulation was tested in a single dose bioavailability study in 20 patients, including both B-cell cancer and AML patients, and across 5 dose levels (10mg to 200mg). The G3 formulation then was evaluated in R/R AML patients with continuous dosing using two different dose levels (50mg BID and 200mg BID) in a total of 11 patients. Data show the G3 formulation dosed at 200mg twice daily can achieve 2-3uM steady state plasma levels, with approximately 10-fold better absorption, and interestingly even better tolerability, than the original G1 formulation. Thus, the G3 formulation achieved the desired plasma exposure benchmark and can serve as the formulation of choice for future studies with LUX. Aptose is exploring alternative development paths and collaborations to advance LUX as a single agent or in combination with VEN to treat defined R/R patient populations of high unmet need. Multiple Planned Value-creating Milestones Ahead TUS/VEN doublet synopsis in R/R AML: EHA 2024 TUS/VEN/HMA planned initiation of pilot triplet study in 1L AML: Summer 2024 Triplet pilot dose escalation planned with early CR/MRD/safety data in 1L AML: ASH 2024 Triplet pilot completed with CR/MRD data and dose selection: EHA 2025 Triplet initiation of Ph2/Ph3 pivotal program: 2H 2025 FINANCIAL RESULTS OF OPERATIONS Balance Sheet Data (unaudited) ($ in thousands) December 31, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 9,252 $ 46,959 Working capital (3,375 ) 37,235 Total assets 12,989 51,027 Non-current liabilities 621 1,002 Deficit (515,537 ) (464,330 ) Total shareholders’ equity (2,901 ) 37,741 Cash and cash equivalents, January 31, 2024 (unaudited) was $18.6 million, after gross proceeds from January 2024 financings (unaudited) of $13.7 million. Total cash and cash equivalents and investments as of December 31, 2023, were $9.3 million, a decrease of $37.7 million as compared to $47.0 million at December 31, 2022. Based on current operations, the Company expects that cash on hand and available capital provide the Company with sufficient resources to fund planned Company operations including research and development through August of 2024. Working capital is a non-GAAP measure and represents cash, cash equivalents, investments, prepaid expenses and other current assets less current liabilities. Common shares issued and outstanding as at March 26, 2024 were 15,717,701. Statements of Operations Data (unaudited) Year ended December 31, (in thousands except per Common Share data) 2023 2022 Revenues $ - $ - R&D, related party 3,492 3,556 Research and development expenses 33,273 24,532 General and administrative expenses 15,591 14,514 Net finance income 1,149 779 Net loss $ (51,207 ) $ (41,823 ) Basic and diluted loss per Common Share $ (7.58 ) $ (6.80 ) Weighted average number of common shares outstanding used in the calculation of basic loss per share 6,755 6,151 Net loss for the year ended December 31, 2023 increased by $9.4 million to $51.2 million, as compared to $41.8 million for the comparable period in 2022. Research and Development Expenses The research and development expenses for years ended December 31, 2023, and 2022 are as follows: Twelve months ended December 31, (in thousands) 2023 2022 Program costs – Tuspetinib $ 24,925 $ 10,083 Program costs – Luxeptinib 3,510 8,426 Program costs – APTO-253 40 141 Personnel related expenses 6,878 7,181 Stock-based compensation 1,373 2,218 Depreciation of equipment 39 39 Total $ 36,765 $ 28,088 R&D expenses increased by $8.7 million to $36.8 million for the year ended December 31, 2023, as compared with $28.1 million for the comparative period in 2022. Changes to the components of our R&D expenses presented in the table above are primarily related to the following activities: Program costs for tuspetinib increased by $14.8 million. The higher program costs for tuspetinib in 2023 represent the enrollment of patients in our APTIVATE clinical trial, our healthy volunteer trial, manufacturing activities to support clinical development, purchase of clinical trial materials, and related expenses. Program costs for luxeptinib decreased by approximately $4.9 million, primarily due to lower clinical trial costs and lower manufacturing costs as a result of the current formulation requiring less API than the prior formulation. Program costs for APTO-253 decreased by approximately $101 thousand due to the Company's decision on December 20, 2021, to discontinue further development of APTO-253. Personnel-related expenses decreased by $0.3 million due to lower headcount in 2023. Stock-based compensation decreased by approximately $845 thousand in the year ended December 31, 2023, compared with the year ended December 31, 2022, primarily due to stock options granted with lower grant date fair values in the current period. General and Administrative Expenses General and administrative expenses consist primarily of salaries, benefits, and travel, including stock-based compensation for our executive, finance, business development, human resources, and support functions. Other general and administrative expenses and professional fees include auditing, and legal services, investor relations and other consultants, insurance. and facility related expenses. We expect that our general and administrative expenses will increase for the foreseeable future as we incur additional costs associated with being a publicly traded company and to support our pipeline of activities. We also expect our intellectual property related legal expenses to increase as our intellectual property portfolio expands. The general and administrative expenses for the years ended December 31, 2023 and 2022 are as follows: Year ended December 31, (in thousands) 2023 2022 General and administrative, excluding items below: $ 13,262 $ 11,444 Stock-based compensation 2,280 2,989 Depreciation of equipment 49 81 Total $ 15,591 $ 14,514 General and administrative expenses increased by approximately $1.1 million $15.6 million for the year ended December 31, 2023, as compared with $14.5 million for the comparative period in 2022. The increase was primarily as a result of higher salaries expenses, higher professional fees, and higher travel expenses, partly offset by a decrease in stock-based compensation costs. Stock-based compensation decreased by $709 thousand mostly as a result of options having a lower grant date fair value as compared with the options granted in the comparative period. Conference Call & Webcast: Date: Tuesday, March 26, 2024 Time: 5:00 PM ET Audio Webcast Only: link Q&A Participant Registration Link*: link ( ) *Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call. They also will have the option to take advantage of a Call Me button and the system will automatically dial out to connect to the Q&A session. The audio webcast also can be accessed through a link on the Investor Relations section of Aptose’s website here. A replay of the webcast will be available on the company’s website for 30 days. The press release, the financial statements and the management’s discussion and analysis for the year ended December 31, 2023 will be available on SEDAR at and EDGAR at . AboutAptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit . ForwardLookingStatements This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements regarding the Company’s clinical development plans, the clinical potential, anti-cancer activity, therapeutic potential and applications and safety pro tuspetinib and luxeptinib, clinical trials, alternative development paths and collaborations to advance luxeptinib, upcoming milestones, expected increase of expenses and statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects and other risks detailed from time-to-time in our ongoing current reports, quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: AptoseBiosciencesInc. LifeSciAdvisors,LLC Susan Pietropaolo Dan Ferry, Managing Director Corporate Communications & Investor Relations 617-430-7576 201-923-2049 Daniel@LifeSciAdvisors.com spietropaolo@aptose.com

NEW YORK, March 8, 2024 /PRNewswire/ -- Insights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows. The same findings also support experimental treatment strategies for autoimmune diseases, in which the immune system attacks the body, because stimulating the action of PD-1, as opposed to restricting it, can potentially block an overactive immune response. Led by researchers at NYU Langone Health's Perlmutter Cancer Center and the University of Oxford, the study is publishing in the journal Science Immunology online March 8. The study results revolve around the body's immune system, which is primed to attack virally infected and cancerous cells while leaving normal cells alone. To spare normal cells from immune attack, the system uses "checkpoints," sensors on the surface of immune cells, including T cells, which turn them off or dampen activation when they receive the right signal. The immune system recognizes tumors as abnormal, but cancer cells can hijack checkpoints to turn off immune responses. Among the most important checkpoints is a protein called programmed cell death receptor 1 (PD-1), which is shut down by a relatively new drug class called checkpoint inhibitors to make tumors "visible" again to immune attack. Such drugs are at least somewhat effective in a third of patients with a variety of cancers, say the study authors, but the field is urgently seeking ways to improve their performance and scope. At the same time, PD-1 signaling is slowed in autoimmune diseases like rheumatoid arthritis, lupus, and type 1 diabetes, such that the action of unchecked immune cells creates inflammation that can damage tissues. Agonists, drugs that stimulate PD-1, are now showing promise in clinical trials. Many immune checkpoints are receptors on the surface of T cells that act to translate docking information from the outside of the cell to the signaling portion of the receptor inside the cell. Connecting the outside-of-the-cell portion of PD-1 with the inside portion is the transmembrane segment. Many immune receptors function in pairs called dimers, but to date, PD-1 has been thought to function alone, not in the dimer form. Study results showed that PD-1 forms a dimer through interactions of its transmembrane segment. Researchers say this finding is in sharp contrast to other immune receptors, which typically form dimers through the segment of the receptor that is outside the cell. Further immune cell testing in mice showed that encouraging PD-1 to form dimers, specifically in the transmembrane domain but not in its outer or inner regions, increased its ability to suppress T cell activity, while decreasing transmembrane dimerization lowered PD-1's ability to inhibit immune cell activity. "Our study reveals that the PD-1 receptor functions optimally as dimers driven by interactions within the transmembrane domain on the surface of T cells, contrary to the dogma that PD-1 is a monomer," said study lead investigator and physician-scientist Elliot Philips, MD, PhD, an internal medicine resident at NYU Grossman School of Medicine and Perlmutter Cancer Center. Philips is also an alumnus of the Vilcek Institute of Biomedical Sciences at NYU. "Our findings offer new insights into the molecular workings of the PD-1 immune cell protein that have proven pivotal to the development of the current generation of anticancer immunotherapies, and which are proving essential in the design and developing of the next generation of immunotherapies for autoimmune diseases," said study co-senior investigator and cancer immunologist Jun Wang, PhD. Wang is an assistant professor in the Department of Pathology at NYU Grossman and Perlmutter. "Our goal is to use our new knowledge of the functioning of PD-1 to determine if weakening its dimerization, or pairing, helps make anticancer immunotherapies more effective, and just as importantly, to see if strengthening its dimerization helps in the design of agonist drugs that quiet overactive T cells, tamping down the inflammation seen in autoimmune diseases," said study co-senior investigator and structural biologist Xiang-Peng Kong, PhD. "Presently, research efforts have focused on strengthening PD-1 interactions with its ligands, or signaling molecules, involved with inhibiting T cell action. "Our new study suggests that efforts to design better drugs should focus on increasing or decreasing PD-1's dimerization to manipulate T cell function," said Kong, a professor in the Department of Biochemistry and Molecular Pharmacology at NYU Grossman and Perlmutter. Among the study's other findings was that a single change in the amino acid structure of the transmembrane segment can act to either enhance or diminish the inhibitory function of PD-1 in immune responses. The team plans further investigations of PD-1 inhibitors and agonists to see if they can tailor what they say are more effective, "rationally designed" therapies for both cancer and autoimmune disorders. Funding support for the new study was provided by National Institutes of Health grants R01AI125640, R37CA273333, T32AR069515, and T32GM007308. Additional funding support was provided by NYU Grossman School of Medicine, Kennedy Trust for Rheumatology Research grant 100262Z/12/Z; Research Council of Norway grant 275466, in conjunction with Marie Sklodowska-Curie Actions; Wellcome Trust grant 108869/Z/15/Z; the Melanoma Research Alliance; and a pilot award from the NYU Colton Center for autoimmunity. Wang has been a paid consultant to RootPath Genomics, Bristol Myers Squibb, and Hanmi Pharmaceutical and is a founder, equity holder, and consultant to Remunix. These interests and relationships are being managed in accordance with the policies of NYU Langone Health. Besides Philips, Wang, and Kong, other NYU Langone researchers involved in this study are colead investigator Jia Liu, and coinvestigators Charles Ng, Ian Ahearn, Ruimin Pan, Christina Luo, Alexander Leithner, Zhihua Qin, and Dan Littman, who is also a Howard Hughes Medical Institute investigator. Other study coinvestigators include Audun Kvalvaag, at Oslo University, Norway; Alexander Morch and co-senior investigator Michael Dustin, at the University of Oxford, United Kingdom; Anna Tocheva, at the Icahn School of Medicine at Mount Sinai in New York; Hong Liang and Yong Zhou, at the University of Texas in Houston; Antonio Garcia-Espana, at the University of Rovira i Virgili in Tarragona, Spain; and Adam Mor, at Columbia University in New York. STUDY DOI 10.1126/sciimmunol.ade6256 Media Inquiries: David March 212-404-3528 [email protected] SOURCE NYU Langone Health System

DUBLIN, March 7, 2024 /PRNewswire/ -- The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering. Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. Fully revised and updated, the report provides details of co-promotion and co-marketing deals from 2016 to 2024, the report provides access to co-promotion and co-marketing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of co-promotion and co-marketing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of co-promotion and co-marketing deals. Chapter 4 provides a review of the leading co-promotion and co-marketing deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 25 most active co-promotion and co-marketing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of co-promotion and co-marketing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-promotion and co-marketing deal. The deal directory includes a comprehensive listing of all co-promotion and co-marketing deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing alliances. Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits: Understand deal trends since 2016 Browse co-promotion and co-marketing deals Benchmark analysis - identify market value of transactions Financials terms Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology includes: Trends in co-promotion and co-marketing dealmaking in the biopharma industry Overview of co-promotion and co-marketing deal structure Directory of co-promotion and co-marketing deal records covering pharmaceutical and biotechnology The leading co-promotion and co-marketing deals by value Most active co-promotion and co-marketing dealmakers The leading co-promotion and co-marketing partnering resources Analyzing contract agreements allows due diligence of: What are the rights granted or optioned? What rights are granted by the agreement? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are intellectual property rights handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in co-promotion and co-marketing dealmaking 2.1. Introduction 2.2. Definition of co-promotion and co-marketing deals 2.3. Trends in co-promotion and co-marketing deals since 2016 2.3.1. Co-promotion and co-marketing dealmaking by year, 2016-2024 2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2016-2024 2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2016-2024 2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2016-2024 2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2016-2024 2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2016-2024 2.4. Reasons for entering into co-promotion and co-marketing partnering deals 2.5. The future of co-promotion and co-marketing deals Chapter 3 - Overview of co-promotion and co-marketing deal structure 3.1. Introduction 3.2. Co-promotion and co-marketing agreement structure Chapter 4 - Leading co-promotion and co-marketing deals 4.1. Introduction 4.2. Top co-promotion and co-marketing deals by value Chapter 5 - Top 25 most active co-promotion and co-marketing dealmakers 5.1. Introduction 5.2. Top 25 most active co-promotion and co-marketing dealmakers Chapter 6 - Co-promotion and co-marketing deals including contracts directory 6.1. Introduction 6.2. Co-promotion and co-marketing deals with contracts 2016-2024 Deal directory Deal directory - Co-promotion and co-marketing dealmaking by companies A-Z Deal directory - Co-promotion and co-marketing dealmaking by therapy area Deal directory - Co-promotion and co-marketing dealmaking by technology type Some of the companies featured 3D Medicines 4D Molecular Therapeutics Abbvie AbCellera Biologics ALK-Abello Allegis Pharmaceuticals Allergan Bausch & Lomb Baxalta Bayer Beam Therapeutics BeiGene Beijing Minhai Biotechnology Belharra Therapeutics Belintra Berlin Chemie BioAge Labs Biogen Biognosys Biological Industries BioNano Genomics BioNTech Cipher Pharmaceuticals Concordia Pharmaceuticals CRISPR Therapeutics CrossLink Bioscience CSL Dova Pharmaceuticals Dovetail Genomics DualityBio Eagle Genomics Eagle Pharmaceuticals EA Pharma Eli Lilly Empatica Enterome Bioscience Epizyme Eton Pharmaceuticals Exact Sciences Fabric Genomics Gilead Sciences Glenmark Pharmaceuticals Goldfinch Bio GSK GT Research H3 Biomedicine Halyard Health Hanmi Pharmaceutical Harbin Pharmaceutical Group HD Biosciences Iconic Therapeutics Idorsia IGM Biosciences Illumina Immatics Biotechnologies Immunicon ImmunityBio Ionis Pharmaceuticals Ironwood Pharmaceuticals iTeos Therapeutics Janssen Biotech Janssen Pharmaceuticals Jiangsu Alphamab Konica Minolta Kowa Pharmaceuticals America KSQ Therapeutics Kyorin Pharmaceutical Kyowa Hakko Kirin Kyverna Therapeutics Luqa Pharmaceuticals Luxcel Biosciences Lygos Macrogenics Manchester BIOGEL MannKind Biopharmaceuticals Medicines360 MedImmune Medovate MEI Pharma Menarini Merck and Co Merck KGaA Mersana Therapeutics Mesoblast Metagenomi Metavant Microsoft Nkarta Therapeutics Novartis Novo Nordisk nRichDX Numab Otonomy Otsuka Oxford BioMedica Pacira Biosciences Paragon Bioservices Pfizer Phil Prothena Provention Bio PSI (Population Services International) Purdue Pharma Pure Pharmaceuticals QED Therapeutics Qiagen Quanta Radius Health Rainbow Scientific Rakuten Medical Recludix Pharma RedHill Biopharma RefleXion Medical Regeneron Pharmaceuticals Regenxbio Relay Therapeutics Repare Therapeutics Resonant Specific Technologies Revolution Medicines Rigel Pharmaceuticals Roche Sanofi Seren Pharmaceuticals Seres Therapeutics Shimadzu Shionogi Silicon Biosystems Simcere Pharmaceuticals Sirtex Medical SK Biopharmaceuticals Solid Biosciences Sonoma BioTherapeutics Sosei SparingVision Stealth BioTherapeutics Stoke Therapeutics StrideBio Tango Therapeutics Teijin Telix Pharmaceuticals Terumo Blood and Cell Technologies Tetraphase Pharmaceuticals Teva Pharmaceutical Industries Theravance Thermo Fisher Scientific Tilak Healthcare Tilray Titan Pharmaceuticals Tolmar Urovant Sciences US WorldMeds Verity Pharmaceuticals Vertex Pharmaceuticals Vertice Pharma Vifor Pharma Voyager Therapeutics WAVE Life Sciences Xellia Pharmaceuticals Xencor ZAI Laboratory Zymeworks For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets